tiprankstipranks
Trending News
More News >

Cellectis Reports 2024 Financial Results and Strategic Advances in CAR T-Cell Therapies

Story Highlights
  • Cellectis focuses on developing innovative therapies using TALEN® genome editing.
  • Cellectis strengthens its CAR T-cell therapy market position with strategic advances and AstraZeneca partnership.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Cellectis Reports 2024 Financial Results and Strategic Advances in CAR T-Cell Therapies

Confident Investing Starts Here:

An announcement from Cellectis SA ( (FR:ALCLS) ) is now available.

Cellectis has announced its financial results for the fourth quarter and fiscal year 2024, alongside a business update. The company is advancing its clinical trials, particularly UCART22 and UCART20x22, with significant regulatory designations from the FDA and European Commission, enhancing its position in the CAR T-cell therapy market. Its strategic partnership with AstraZeneca, including a $140 million investment, supports the development of next-generation genomic medicines, with a strong cash position projected to last until mid-2027.

More about Cellectis SA

Cellectis SA is a clinical-stage biotechnology company specializing in the development of innovative therapies using its TALEN® genome editing technology. The company focuses on creating treatments for serious diseases, particularly through its allogeneic CAR T-cell therapies and gene editing programs.

YTD Price Performance: -16.67%

Average Trading Volume: 950

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $95.46M

For detailed information about ALCLS stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App